Merck KGaA

After a couple of months of talks, Merck KGaA has inked a deal to buy SpringWorks Therapeutics which will expand its presence in the US and sharpen the firm’s focus in rare diseases and cancer. The pu

At a time when accessing capital has become increasingly difficult, leaving more and more biopharma firms to consider a range of less-than-stellar strategic alternatives, Alis Biosciences has emerged

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s

The UK’s originator drugs and generics industries are at odds over a rise in the clawbacks that companies must pay the government on the sales of branded medicines to the National Health Service under